Mrs Sudha Sundar

 

Senior Lecturer in Gynaecological Oncology

School of Cancer Sciences

Sundar-sudha-Cropped-110x146

Contact details

School of Cancer Sciences
Vincent Drive
University of Birmingham
Birmingham
B15 2TT

About

Dr Sundar is a Senior Lecturer in Gynaecological Oncology and a Consultant in Gynaecological Oncology at the Pan Birmingham Gynaecological Cancer Centre, City Hospital. 

Teaching

Clinical Lead Fulltime MSc in Oncology

Year 4 Oncology Module lead for MBCh

Recipient of the ‘Award for Excellence in Teaching and Supporting Learning’ for 2010-11

Postgraduate supervision

If you are interesting in studying in any of subject areas listed below please contact Sudha Sundar.

Research

Sudha’s research programme  investigates clinical challenges in patients with gynaecological cancer, combining secondary research/clinical trials/studies and translational research, particularly incorporating stratified medicine. (More...)

 

GRANT FUNDING

ROCkETS – Refining Ovarian cancer Test accuracy scores. Chief Investigator.

£1,00,0037

Collaboration with Prof Jon Deeks, BCTU, KU Leuven IOTA group, Prof Usha Menon, UCL and Prof Richard Neal, North Wales Primary care group, University of Bangor.

This complex project will derive and validate risk models that improve on the Risk of Malignancy Index for Ovarian cancer

 

Sudha Sundar, co-PI. FOAM trial. Folic acid for hot flushes in menopausal patients with breast and ovarian cancer. Approximately 250,000£. RfPB. July 2012.

Sudha Sundar, (co PI), collaborating with Prof Andrea Rockall, Imaging  at Barts (CI) for the MAPPING study.  Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma. BIDD grant from Cancer Research UK. £ 225,698, Nov 2010.

Sudha Sundar. ( co PI), Key collaborators – Prof Tracy Roberts, Health economics, Birmingham and Prof Khalid Khan, now at Barts, CI. Sentinel lymph node status in vulval cancer: Systematic quantitative reviews and decision analytic model based economic evaluation.  HTA £229,000 June 2010.

Sudha Sundar (co-PI). Key collaborators – Prof Tracy Roberts, Health economics, Birmingham and Prof Khalid Khan, now at Barts, CI Clinical effectiveness of PET-CT imaging in restaging recurrent cervical cancer: Systematic review of evidence and economic modelling. HTA £332,000, Jan 2010.

Sudha Sundar, PI. Evaluation of autotaxin and lipid metabolites in ovarian cancer. Sandwell and West Birmingham Hospitals Research and Development Award – January 2009 £24,000 Jan 2009.

Collaboration with Prof Roy Bicknell. Cobalt Appeal Fund Fellowship – May 2007.  £84,450. To investigate antiangiogenic and epidermal growth factor receptor antagonists as novel therapies in poor prognostic endometrial cancer.

Other activities

  • Member of Gynaecological Cancer Clinical Studies Group, NCRI (2008-2013)
  • Council member, British Gynaecological Cancer Society, April 2011- date
  • Chair, Guidelines Committee, British Gynaecological Cancer Society, 2012 - date 

Publications

Sentinel lymph node biopsy in vulval cancer: systematic review and meta-analysis.Catherine Meads, Andrew Sutton, Sylwia Małysiak, Monika Kowalska, Anna Zapalska, Ewelina Rogozińska, Peter Baldwin, Adam Rosenthal, Raji Ganesan, Ewa Borowiack, Pelham Barton, Tracy Roberts, Khalid Khan, Sudha Sundar. Br J Cancer. 2014 Jun 10;110(12):2837-46. doi: 10.1038/bjc.2014.205. Epub 2014 May 27.

Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis. Auguste P, Barton P, Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, Martin-Hirsch P, Borowiack E, Khan K, Sundar S, Roberts T.

BJOG. 2013 Dec 3. doi: 10.1111/1471-0528.12460. [Epub ahead of print]

Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer. Sutton AJ , Barton P , Sundar S , Meads C , Rosenthal AN , Baldwin P , Khan K , Roberts TE . Br J Cancer. 2013 Oct 15. doi: 10.1038/bjc.2013.631.

Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, Martin-Hirsch P, Borowiack E, Auguste P, Barton P, Roberts T, Khan K, Sundar S.

BJOG. 2013 Dec 3. doi: 10.1111/1471-0528.12488. epub before print

Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer. Sutton AJ , Barton P , Sundar S , Meads C , Rosenthal AN , Baldwin P , Khan K , Roberts TE . Br J Cancer. 2013 Oct 15. doi: 10.1038/bjc.2013.631.

PET-CT imaging in detecting and managing recurrent cervical cancer: Systematic review of evidence, elicitation of subjective probabilities and economic modelling. Authors: Catherine Meads, Peter Auguste, Clare Davenport, Sylwia Małysiak, Sudha Sundar, Monika Kowalska, Anna Zapalska, Peter Guest, Shakila Thangaratinam, Pierre Martin-Hirsch, Ewa Borowiack, Pelham Barton, Tracy Roberts, Khalid Khan. Peer reviewed HTA report, in press.

Sentinel lymph node (SLN) status in vulval cancer: Systematic reviews of test accuracy and decision analytic model-based economic evaluation.  Catherine Meads, Andrew Sutton, Sylwia Małysiak, Monika Kowalska, Anna Zapalska, Ewelina Rogozińska, Peter Baldwin, Adam Rosenthal, Raji Ganesan, Ewa Borowiack, Pelham Barton, Tracy Roberts, Sudha Sundar, Khalid Khan. Peer reviewed HTA report, in press.

Sundar S, Wu J, Hillaby K, Yap J, Lilford R. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol. 2011 Dec 8. [Epub ahead of print]

C. Connolly, K. K. Chan, K. Singh, S. Sundar, D. Luesley, M. S. Anwar, I. N. Fernando;
Outcomes following interval debulking surgery in primary peritoneal carcinoma. J Clin Oncol 29: June 9; 2011 (suppl; abstr e15515)

Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S.  Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011 Apr 26;104(9):1505-10.

Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F, Sundar S.  Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.  Br J Cancer. 2011 May 10;104(10):1611-8. 

Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S.  Should grade 3 endometrioid carcinoma be considered a type 2 cancer - a clinical and pathological evaluation. Available online August 2011 doi:10.1016/j.ygyno.2011.07.030

Nevin J, Luesley D, Chan KK, Singh K, Balega J, Sundar S.  Meeting the challenge of developing and maintaining radical hysterectomy skills. BJOG. 2010 Jan;117(1):1-4. 

Maloney SL, Sullivan DC, Suchting S, Herbert JM, Rabai EM, Nagy Z, Barker J, Sundar S, Bicknell R.  Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane. Br J Cancer. 2009 Sep 15;101(6):957-66.

Jadoon BA, Kehoe S, Romain K, Clelland C, Sundar SS.  Analysis of outcome in women with borderline glandular change on cervical cytology.  Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):83-5

Sundar SS, Ganesan TS.  Role of lymphangiogenesis in cancer. J Clin Oncol. 2007 Sep 20;25(27):4298-307. 

Royal College of Obstetricians and Gynaecologists – Specialist advisory committee commissioned opinion paper.  Optimum Surgery in Advanced Ovarian Cancer. Naik, McIndoe, Mould and Sundar. http://www.rcog.org.uk/womens-health/clinical-guidance/ovarian-cancer-optimum-surgery-advanced-stage-sac-opinion-paper-25

Back to top